Multimedia content is supported by an unrestricted educational grant from:

Scientific Agenda

Session VI: Antifungal trial design
Moderators: James I. Ito, MD and Jack D. Sobel, MD

Candidiasis: Why we need to change our trial strategy
Luis Ostrosky-Zeichner, MD, FACP

Antifungal trial design for mould-active agents: Time to break the mold
Elias J. Anaissie, MD

Pharmacodynamics: A frequently forgotten (but essential) tool of antifungal trial design
George L. Drusano, MD

Pharmacogenomics of antifungal agents: An update
David R. Andes, MD

Special lecture: TH1-TH2 in aspergillosis
David A. Stevens, MD